Brief: Cutia Therapeutics Says Registrational Phase III Clinical Trial Of CU-40102 Reached Primary Endpoint
11/12/2023 01:21
Dec 11 (Reuters) - Cutia Therapeutics 2487.HK :
* REGISTRATIONAL PHASE III CLINICAL TRIAL OF CU-40102 IN PRC
HAS
REACHED PRIMARY ENDPOINT
Source text for Eikon: ID:nHKScgLj6G
Further company coverage: 2487.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cutia Therapeutics
See all newsBrief: Cutia Therapeutics To Implement Share Repurchase Program From Oct 2 To Dec 31
Brief: Cutia Therapeutics Says Cu-40102 Bags Marketing Approval From Macao Pharmaceutical Administration Bureau
Brief: Cutia Therapeutics Says Nmpa Accepts Biologics License Application For Cu-20101
Brief: Cutia Therapeutics Posts HY Loss Of RMB180.4 MLN
Brief: Cutia Therapeutics Says CU-30101 Obtains Drug Marketing Authorization By NMPA China